NEW YORK (GenomeWeb) – Quidel announced after the close of the market Tuesday that it received 510(k) clearance from the US Food and Drug Administration to market the Solana Strep Complete Assay for rapid and qualitative detection and differentiation of Streptococcus pyogenes (Group A beta-hemolytic Streptococcus) and Streptococcus dysgalactiae (pyogenic Group C and G beta-hemolytic Streptococcus).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.